Articles dans des revues avec comité de lecture (182)
  1. 82. Jensen, D. M., Ouzan, D., Wright, M., Morano, L. E., Buynak, R., Bourlière, M., Hassanein, T., Nishiguchi, S., Kao, J. H., Omata, M., Paik, S., Asselah, T., Wong, D., Tam, E., Kaita, K., Victor Feinman, S., Stern, J. J., Scherer, J., Quinson, A. M., Voss, F., Gallivan, J. P., Böcher, W. O., Dieterich, D., Ferenci, P., Foster, G. R., Sulkowski, M., Zeuzem, S., Mantry, P., Yoshida, E. E., & Moreno, C. (2016). Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: Pooled analysis of two phase 3 trials. Annals of Hepatology, 15(3), 333-349. doi:10.5604/16652681.1198803
  2. 83. Moreno, C., Deltenre, P., Senterre, C., Louvet, A., Gustot, T., Bastens, B., Hittelet, A.-B., Piquet, M.-A., Laleman, W., Orlent, H., Lasser, L., Serste, T., Starkel, P., De Koninck, X., Dastis, S. N., Delwaide, J., Colle, I., de Galocsy, C., Francque, S., Langlet, P., Putzeys, V., Reynaert, H., Degré, D., & Trepo, E. (2016). Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. Gastroenterology, 150(4), 903-10.e8. doi:10.1053/j.gastro.2015.12.038
  3. 84. Feld, J. J., Reindollar, R. R., Larsen, L., Bolotin-Fukuhara, M., Howieson, K., Polepally, A. R., Pangerl, A., Shulman, N. N., Poordad, F., Moreno, C., Trinh, R., Tam, E., Bourgeois, S., Horsmans, Y., Elkhashab, M., Bernstein, D., & Younes, Z. (2016). Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. Journal of hepatology, 64(2), 301-307. doi:10.1016/j.jhep.2015.10.005
  4. 85. Arain, A., Verrando, R., Bruckers, L., Matheï, C., Buntinx, F., van Vlierberghe, H., Francque, S., Laleman, W., Moreno, C., Janssens, F., Nevens, F., Bourgeois, S., Robaeys, G., De Galocsy, C., Henrion, J., Deltenre, P., D'Heygere, F., George, C., Bastens, B., & Van Overbeke, L. (2016). Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs. Journal of medical virology, 88(1), 94-99. doi:10.1002/jmv.24308
  5. 86. Asselah, T., Ferenci, P., Yu, Y., Redman, R., Pilot-Matias, T., Mobashery, N., Hezode, C., Qaqish, R. R., Elkhashab, M., Hassanein, T., Papatheodoridis, G., Feld, J. J., Moreno, C., & Zeuzem, S. (2016). Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. The Lancet Gastroenterology and Hepatology, 1(1), 25-35. doi:10.1016/S2468-1253(16)30001-2
  6. 87. Schreiber, J., McNally, J., Chodavarapu, K., Svarovskaia, E., & Moreno, C. (2016). Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. Hepatology, 64(3), 983-985. doi:10.1002/hep.28636
  7. 88. Marot, A., Trepo, E., Doerig, C., Moreno, C., Moradpour, D., & Deltenre, P. (2015). Systematic review with meta-analysis: self-expanding metal stents in patients with cirrhosis and severe or refractory oesophageal variceal bleeding. Alimentary pharmacology & therapeutics, 42(11-12), 1250-1260. doi:10.1111/apt.13424
  8. 89. Dubuquoy, L., Leteurtre, E., Cannesson-Leroy, A., Dharancy, S., Moreno, C., Pruvot, F. R. E. F., Bataller, R., Mathurin, P., Louvet, A., Lassailly, G., Truant, S., Boleslawski, E., Artru, F., Maggiotto, F., Gantier, E., & Buob, D. (2015). Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut, 64(12), 1949-1960. doi:10.1136/gutjnl-2014-308410
  9. 90. Buch, S., Stickel, F., Trepo, E., Way, M., Enk, A. H., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., Rietschel, M., McQuillin, A., Frank, J., Kiefer, F., Schreiber, S., Lieb, W., Soyka, M., Semmo, N., Aigner, E., Datz, C., Schmelz, R., Brückner, S., Zeissig, S., Stephan, A.-M., Wodarz, N., Devière, J., Clumeck, N., Sarrazin, C., Lammert, F., Gustot, T., Deltenre, P., Völzke, H., Lerch, M. M., Mayerle, J., Eyer, F., Schafmayer, C., Cichon, S., Nothen, M., Nothnagel, M., Ellinghaus, D., Huse, K., Franke, A., Zopf, S., Hellerbrand, C., Moreno, C., Franchimont, D., Morgan, M. Y., & Hampe, J. (2015). A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nature genetics, 47(12), 1443-1448. doi:10.1038/ng.3417
  10. 91. Degré, D., Laleman, W., Verhelst, X., Lamproye, A., Vanwolleghem, T., Gustot, T., Starkel, P., Lanthier, N., Michielsen, P., Delwaide, J., Van Vlierberghe, H., Nevens, F., & Moreno, C. (2015). Multicenter Belgian experience of sofosbuvir medical need program in pre- and post liver transplantation: safety and efficacy results. Transplant international, 28(Supplément 4), 21. doi:10.1111/tri.12700
  11. 92. Lepida, A., Iraqi, W., DeMasi, R., Lonjon-Domanec, I., Moreno, C., Wedemeyer, H., Colombo, M., Fernández, I., Abdurakhmanov, D., Ferreira, P. A., Strasser, S., Urbanek, P., Mangia, A., & Calleja, J. L. U. J. (2015). Final results of the telaprevir access program: Fibroscan values predict safety and efficacy in hepatitis c patients with advanced fibrosis or cirrhosis. PloS one, 10(9). doi:10.1371/journal.pone.0138503
  12. 93. Coilly, A., Roche, B., Antonini, T. M., Guillaud, O., Lebray, P., Radenne, S., Saouli, A. C., Calmus, Y., Alric, L., Debette-Gratien, M., De Ledinghen, V., Dumortier, J., Durand, F., Duvoux, C., Samuel, D., Duclos-Vallée, J.-C., Botta-Fridlund, D., Latournerie, M., Leroy, V., Pageaux, G.-P., Agostini, H., Giostra, E., & Moreno, C. (2015). Multicenter experience with boceprevir or telaprevir to treat hepatitis C recurrence after liver transplantation: When present becomes past, what lessons for future? PloS one, 10(9), e0138091. doi:10.1371/journal.pone.0138091
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Suivant >>